Drugs / BIC/FTC/TAF
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT04233879 Comparator | Feb 2020 → Nov 2022 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIC/FTC/TAF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04233879 ↗ |
| Route | Oral | “BIC/FTC/TAF 50/200/25 mg FDC single tablet taken once daily by mouth.” NCT04233879 ↗ |